Insider Transactions in Q1 2023 at Laboratory Corp Of America Holdings (LH)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
423
+2.49%
|
-
|
|
Feb 11
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
290
+4.9%
|
-
|
|
Feb 11
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
180
+19.21%
|
-
|
|
Feb 11
2023
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
236
+10.4%
|
-
|
|
Feb 11
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
423
+5.62%
|
-
|
|
Feb 11
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110
+4.77%
|
-
|
|
Feb 07
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
219
-3.94%
|
$53,217
$243.01 P/Share
|
|
Feb 07
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
409
-5.76%
|
$99,387
$243.01 P/Share
|
|
Feb 06
2023
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,368
-5.93%
|
$333,792
$244.5 P/Share
|
|
Feb 06
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-2.08%
|
$36,844
$244.5 P/Share
|
|
Feb 06
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
164
-1.18%
|
$40,016
$244.5 P/Share
|
|
Feb 06
2023
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-0.74%
|
$63,684
$244.5 P/Share
|
|
Feb 06
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.54%
|
$26,352
$244.5 P/Share
|
|
Feb 06
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
164
-1.01%
|
$40,016
$244.5 P/Share
|
|
Feb 06
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-2.43%
|
$12,688
$244.5 P/Share
|
|
Feb 06
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
81
-1.44%
|
$19,764
$244.5 P/Share
|
|
Feb 06
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-12.58%
|
$20,252
$244.5 P/Share
|
|
Feb 06
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-4.47%
|
$20,496
$244.5 P/Share
|
|
Feb 04
2023
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,507
+13.2%
|
-
|
|
Feb 04
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+7.17%
|
-
|
|
Feb 04
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+3.87%
|
-
|
|
Feb 04
2023
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
970
+2.67%
|
-
|
|
Feb 04
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
374
+1.83%
|
-
|
|
Feb 04
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+3.33%
|
-
|
|
Feb 04
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150
+6.55%
|
-
|
|
Feb 04
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+5.05%
|
-
|
|
Feb 04
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
267
+28.8%
|
-
|
|
Feb 04
2023
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
280
+12.96%
|
-
|
|
Feb 03
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
173
-3.14%
|
$43,769
$253.9 P/Share
|
|
Feb 03
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
324
-4.62%
|
$81,972
$253.9 P/Share
|
|
Feb 02
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-4.59%
|
$19,558
$254.99 P/Share
|
|
Feb 02
2023
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+11.59%
|
-
|
|
Feb 02
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-2.02%
|
$10,414
$254.99 P/Share
|
|
Feb 02
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117
+5.45%
|
-
|
|
Feb 02
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-1.15%
|
$16,256
$254.99 P/Share
|
|
Feb 02
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
237
+4.08%
|
-
|
|
Feb 02
2023
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
805
-3.95%
|
$204,470
$254.99 P/Share
|
|
Feb 02
2023
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,773
+11.99%
|
-
|
|
Feb 02
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
119
-1.67%
|
$30,226
$254.99 P/Share
|
|
Feb 02
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+5.85%
|
-
|
|
Feb 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-16.38%
|
$19,558
$254.99 P/Share
|
|
Feb 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+31.88%
|
-
|
|
Feb 02
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-1.05%
|
$35,814
$254.99 P/Share
|
|
Feb 02
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+3.18%
|
-
|
|
Feb 02
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
102
-0.52%
|
$25,908
$254.99 P/Share
|
|
Feb 02
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
297
+1.48%
|
-
|
|
Feb 02
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-0.91%
|
$36,576
$254.99 P/Share
|
|
Feb 02
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+2.72%
|
-
|
|
Feb 02
2023
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.6%
|
$52,324
$254.99 P/Share
|
|
Feb 02
2023
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
767
+2.17%
|
-
|